Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) released its quarterly earnings results on Monday. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.18), Zacks reports.
Avalo Therapeutics Trading Down 6.7%
AVTX opened at $4.06 on Monday. Avalo Therapeutics has a 12 month low of $4.03 and a 12 month high of $16.00. The business’s 50-day moving average price is $6.14 and its 200-day moving average price is $8.10.
Analysts Set New Price Targets
Several analysts recently weighed in on AVTX shares. Wedbush restated an “outperform” rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Piper Sandler assumed coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target on the stock. HC Wainwright restated a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Stifel Nicolaus initiated coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They issued a “buy” rating and a $36.00 target price for the company. Finally, Jefferies Financial Group initiated coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They issued a “buy” rating and a $23.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.00.
About Avalo Therapeutics
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Featured Articles
- Five stocks we like better than Avalo Therapeutics
- 3 Stocks to Consider Buying in October
- Rocket Lab: Earnings Miss But Neutron Momentum Holds
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 American Outperformers Are Lifting and Initiating Dividends
- What Are Treasury Bonds?
- New Tariffs Hit Film Industry—What It Means for Netflix
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
